title: [Lower and lower cholesterol targets increase adverse effects].
authors.affiliation: Karolinska universitetssjukhuset, Solna. Paul.Hjemdahl@ki.se
authors.forename: Paul
authors.initials: P
authors.lastname: Hjemdahl
authors.forename: Anette
authors.initials: A
authors.lastname: Allhammar
authors.forename: Claire
authors.initials: C
authors.lastname: Heaton
authors.forename: Johan
authors.initials: J
authors.lastname: Hulting
authors.forename: Thomas
authors.initials: T
authors.lastname: Kahan
authors.forename: Rickard
authors.initials: R
authors.lastname: Malmström
authors.forename: Arne
authors.initials: A
authors.lastname: Martinsson
authors.forename: Franz
authors.initials: F
authors.lastname: Rücker
authors.forename: Karin
authors.initials: K
authors.lastname: Schenck-Gustafsson
authors.forename: Jonas
authors.initials: J
authors.lastname: Schwieler
authors.forename: Mattias
authors.initials: M
authors.lastname: Törnerud
authors.forename: Björn
authors.initials: B
authors.lastname: Wettermark
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008078:Cholesterol, LDL / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009135:Muscular Diseases / Q000139:chemically induced; D012206:Rhabdomyolysis / Q000139:chemically induced; D012307:Risk Factors; D019821:Simvastatin / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019821:Simvastatin